Should You Retain Crown Castle Stock in Your Portfolio for Now?
CCI's large portfolio of towers is poised to benefit from the rising wireless connectivity use. Yet, customer concentration and high interest expenses ail.
Wynn Resorts Expands in Europe With Crown London Acquisition
WYNN expands its global footprint with the acquisition of Crown London, enhancing the company's reach in Europe.
Mkango Resources Limited Announces LOI signed with Crown Proptech
Letter of Intent signed with Crown Proptech to list Mkango's Songwe Hill and Pulawy Rare Earths Projects on NASDAQ via a SPAC Merger CALGARY, AB AND LONDON, UK / ACCESSWIRE / January 8, 2025 / Mkango Resources Ltd (AIM:MKA)(TSXV:MKA) ("Mkango"), pursuant to the strategic review for the Songwe Hill Rare Earth project in Malawi ("Songwe") and the Pulawy Rare Earth Separation Plant in Poland ("Pulawy"), is pleased to announce that Mkango's wholly owned subsidiaries, Lancaster Exploration Limited ("Lancaster") and Mkango Polska Sp. Z.o.o (collectively, the "Company"), have signed a non-binding letter of intent ("LOI") for a proposed business combination transaction (the "Transaction") with Crown PropTech Acquisitions ("CPTK"), a Cayman Islands exempted company (OTC: CPTK).
Crown Castle: I Bought The 52-Week Lows, Getting A Yield Of 7%
I started a position in Crown Castle Inc. (CCI) due to its undervaluation, high dividend yield of 7%, and strong business model with significant barriers to entry. Despite a 57.24% decline from its all-time highs, CCI's current valuation metrics, including FFO and EBITDA multiples, indicate it trades at a discount compared to peers. Management's strategic review, including potential fiber business sale and financial discipline, positions CCI for a turnaround and capital appreciation in 2025.
Crown Castle: Attractive Upside Potential, Nearly 7% Dividend Yield
Crown Castle, a leading communications infrastructure REIT, has lagged behind the sector and broader markets over the past year. This underperformance has persisted despite strong fundamentals, including rising data usage and increasing demand for network infrastructure. The stock is trading near its lows, offering an attractive dividend yield of almost 7%.
4 Reasons That Make Crown Castle Stock a Solid Pick for Your Portfolio
Amid rising wireless connectivity usage, CCI's efforts to augment its tower business, as well as fiber and small cells, bode well.
Is Crown Holdings (CCK) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Crown Holdings (CCK) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Crown Castle Stock: A Golden Opportunity Near 52-Week Lows For Long-Term Investors
Crown Castle (CCI) stock is trading near 52-week lows, presenting an attractive entry point for long-term investors with a robust 6.45% dividend yield. CCI's strategic focus on small cells and 5G infrastructure positions it for significant long-term growth, despite current macroeconomic challenges and high capex demands. The company's optimization efforts, including cost-cutting and asset prioritization, have bolstered its financial performance, with impressive profitability metrics and a strong balance sheet.
Is the Options Market Predicting a Spike in Crown Holdings (CCK) Stock?
Investors need to pay close attention to Crown Holdings (CCK) stock based on the movements in the options market lately.
Is Crown Holdings (CCK) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Revance agrees to lower-priced buyout offer by Crown Laboratories
Anti-wrinkle injection maker Revance Therapeutics has agreed to be bought for $3.10 per share by privately held Crown Laboratories, instead of $6.66 per share agreed previously, the two companies said on Monday.
